Form DEFM14A CATALYST PHARMACEUTICALS

Mon, 08 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260608/26617362.html

Form DEFM14A CATALYST PHARMACEUTICALS

Mon, 08 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260608/26617362.html

Form 4 CATALYST PHARMACEUTICALS For: Jun 03 Filed by: Andrews William T.

Fri, 05 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260605/26612021.html

Form 4 CATALYST PHARMACEUTICALS For: Jun 03 Filed by: Andrews William T.

Fri, 05 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260605/26612021.html

Form PREM14A CATALYST PHARMACEUTICALS For: May 28

Thu, 28 May 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260528/26568649.html

Form PREM14A CATALYST PHARMACEUTICALS For: May 28

Thu, 28 May 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260528/26568649.html

H.C. Wainwright Downgrades Catalyst Pharmaceutical Partners (CPRX) to Neutral

Thu, 28 May 2026 10:23:57 -0400

H.C. Wainwright analyst Andrew S. Fein downgraded Catalyst Pharmaceutical Partners (NASDAQ: CPRX) from Buy to Neutral.

For an analyst ratings summary and ratings history on Catalyst Pharmaceutical Partners click here. For more ratings news on Catalyst Pharmaceutical Partners click here.

Shares of Catalyst Pharmaceutical Partners closed at $31.32 yesterday.

Form DEFA14A CATALYST PHARMACEUTICALS

Tue, 12 May 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260512/26474511.html

Form DEFA14A CATALYST PHARMACEUTICALS

Tue, 12 May 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260512/26474511.html

Form 8-K CATALYST PHARMACEUTICALS For: May 11

Mon, 11 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260511/26469843.html

Form 8-K CATALYST PHARMACEUTICALS For: May 11

Mon, 11 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260511/26469843.html

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Mon, 11 May 2026 16:12:00 -0400

Delivered Q1 2026 Total Revenues of $149.4 Million
Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE®
Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026

CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2026 and provided a business update.

Financial Highlights

For the Three Months Ended March

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Mon, 11 May 2026 16:12:00 -0400

Delivered Q1 2026 Total Revenues of $149.4 Million
Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE®
Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026

CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2026 and provided a business update.

Financial Highlights

For the Three Months Ended March

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Mon, 11 May 2026 16:12:00 -0400

Delivered Q1 2026 Total Revenues of $149.4 Million
Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE®
Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026

CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2026 and provided a business update.

Financial Highlights

For the Three Months Ended March

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Mon, 11 May 2026 16:12:00 -0400

Delivered Q1 2026 Total Revenues of $149.4 Million
Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE®
Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026

CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2026 and provided a business update.

Financial Highlights

For the Three Months Ended March

Form 10-Q CATALYST PHARMACEUTICALS For: Mar 31

Mon, 11 May 2026 16:11:00 -0400
si-local-file:///var/storage/secattach/20260511/26469151.html

Form 10-Q CATALYST PHARMACEUTICALS For: Mar 31

Mon, 11 May 2026 16:11:00 -0400
si-local-file:///var/storage/secattach/20260511/26469151.html

Form DEFA14A CATALYST PHARMACEUTICALS

Fri, 08 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260508/26462597.html

Form DEFA14A CATALYST PHARMACEUTICALS

Fri, 08 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260508/26462597.html

Citi Downgrades Catalyst Pharmaceutical Partners (CPRX) to Neutral

Fri, 08 May 2026 10:05:24 -0400

Citi analyst Samantha Semenkow downgraded Catalyst Pharmaceutical Partners (NASDAQ: CPRX) from Buy to Neutral with a price target of $31.50 (from $35.00).
For an analyst ratings summary and ratings history on Catalyst Pharmaceutical Partners click here. For more ratings news on Catalyst Pharmaceutical Partners click here.
Shares of Catalyst Pharmaceutical Partners closed at $31.17 yesterday.

Form DEFA14A CATALYST PHARMACEUTICALS

Thu, 07 May 2026 17:28:00 -0400
si-local-file:///var/storage/secattach/20260507/26455370.html

Form DEFA14A CATALYST PHARMACEUTICALS

Thu, 07 May 2026 17:28:00 -0400
si-local-file:///var/storage/secattach/20260507/26455370.html

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

Thu, 07 May 2026 16:02:00 -0400

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today.

Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned.

About Catalyst Pharmaceuticals,

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

Thu, 07 May 2026 16:02:00 -0400

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today.

Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned.

About Catalyst Pharmaceuticals,

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

Thu, 07 May 2026 16:02:00 -0400

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today.

Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned.

About Catalyst Pharmaceuticals,

StreetInsider.com News Articles

Form DEFM14A CATALYST PHARMACEUTICALS

Form DEFM14A CATALYST PHARMACEUTICALS

Form 4 CATALYST PHARMACEUTICALS For: Jun 03 Filed by: Andrews William T.

Form 4 CATALYST PHARMACEUTICALS For: Jun 03 Filed by: Andrews William T.

Form PREM14A CATALYST PHARMACEUTICALS For: May 28

Form PREM14A CATALYST PHARMACEUTICALS For: May 28

H.C. Wainwright Downgrades Catalyst Pharmaceutical Partners (CPRX) to Neutral

Form DEFA14A CATALYST PHARMACEUTICALS

Form DEFA14A CATALYST PHARMACEUTICALS

Form 8-K CATALYST PHARMACEUTICALS For: May 11

Form 8-K CATALYST PHARMACEUTICALS For: May 11

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Form 10-Q CATALYST PHARMACEUTICALS For: Mar 31

Form 10-Q CATALYST PHARMACEUTICALS For: Mar 31

Form DEFA14A CATALYST PHARMACEUTICALS

Form DEFA14A CATALYST PHARMACEUTICALS

Citi Downgrades Catalyst Pharmaceutical Partners (CPRX) to Neutral

Form DEFA14A CATALYST PHARMACEUTICALS

Form DEFA14A CATALYST PHARMACEUTICALS

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast